# US 2018/0021371 A1 · Novel ophthalmic composition and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021371 A1
- Document ID: US20180021371A1
- Status: Published application
- Kind: A1
- Application number: 15/667,033
- Filed: 2017-08-02
- Published: 2018-01-25
- Earliest claimed: 2015-07-02
- Assignees: Veloce BioPharma, LLC
- Applicants: Veloce BioPharma, LLC
- Inventors: Joseph Capriotti; Kara Capriotti; Jesse Pelletier; Kevin Stewart
- Web page: https://patentgrep.com/patent/US20180021371A1

## CPC

- A61K 31/79: Polymers of vinyl pyrrolidone
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 33/18: Iodine; Compounds thereof
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/38: Cellulose; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described are stable topical formulations useful in the treatment of viral infection, demodex infection and bacterial infection of the eye, and methods of using the compositions for treating viral infection, demodex infection and bacterial infection of the eye.

## Claims

### Claim 1

A stable ophthalmically acceptable gel composition comprising
0.15% to 1.5% povidone-iodine (PVP-I);
30% to 97% dimethyl sulfoxide (DMSO);
2.0% to 5% gelling agent; and
water or isotonic co-solvent
wherein, the composition is a topical ophthalmic gel, free of additional anti-inflammatory drug.

### Claim 2 (depends on 1)

The composition of claim 1, comprising 0.15% to 1.0% PVP-I.

### Claim 3 (depends on 1)

The composition of claim 1, comprising 0.25% to 0.5% PVP-I.

### Claim 4 (depends on 1)

The composition of claim 1, comprising about 0.25% PVP-I.

### Claim 5 (depends on 1)

The composition of claim 1, comprising 30% to 70% DMSO.

### Claim 6 (depends on 1)

The composition of claim 1, comprising 40% to 49% DMSO.

### Claim 7 (depends on 1)

The composition of claim 1, comprising 44% DMSO.

### Claim 8 (depends on 1)

The composition of claim 1, comprising 2% to 3% gelling agent.

### Claim 10 (depends on 1)

The composition of claim 1, comprising:
0.25% PVP-I;
44% DMSO;
2% hydroxyethylcellulose; and
a co-solvent, and
wherein said composition is steroid-free and NSAID-free.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the co-solvent is water or aqueous isotonic solution.

### Claim 12 (depends on 1)

A stable gel composition of claim 1, wherein, the composition is a topical ophthalmic preparation wherein each ingredient is ophthalmically acceptable, and
said ophthalmic gel composition retains at least 85% of titratable iodine in povidone-iodine starting material for at least 72 hours.

### Claim 13 (depends on 12)

The stable gel composition of claim 12 wherein the composition retains at least 85% of titratable iodine in povidone-iodine starting material for at least one month.

### Claim 14 (depends on 12)

The stable gel composition of claim 12 wherein the composition retains at least 85% of titratable iodine in povidone-iodine starting material for up to 12 months.

### Claim 15 (depends on 1)

A method of treating an infectious condition of the eye or eyelid, said method comprising the step of:
applying an effective amount of a stable, topical ophthalmic gel composition of claim 1 to a site of the infection as needed to reduce or eliminate the infection.

### Claim 16 (depends on 15)

The method of claim 15 wherein said infectious condition is selected from the group consisting of blepharitis, conjunctivitis, corneal ulcer, bacterial keratitis, viral keratitis, post-operative endophthalmitis, and endophthalmitis after intravitreal or intracameral injection.

### Claim 17 (depends on 16)

The method of claim 16, wherein the infectious condition is caused by or associated with one or more infectious agents selected from the group consisting of bacteria, demodex, fungus or yeast, and virus.

### Claim 18 (depends on 15)

The method of claim 15 wherein the condition is blepharitis, blepharoconjunctivitis, conjunctivitis, keratitis or infectious corneal ulcer.

### Claim 19 (depends on 15)

The method of claim 15, wherein the infectious agent is a virus.

### Claim 20 (depends on 15)

The method of claim 15, wherein the infectious agent is demodex.

### Claim 29 (depends on 1)

The composition of claim 1 comprising 3% gelling agent.
